Ratings by Cantor Fitzgerald (Yanni Souroutzidis)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/19/2026 | Agomab Therapeutics | AGMB | New Coverage | Overweight (N/A) |
13.73 (13.54) |
-1.38% | Details | |
| 7/1/2026 | Design Therapeutics Inc | DSGN | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/9/2026 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/12/2026 | Design Therapeutics Inc | DSGN | New Coverage | Overweight (N/A) |
15.61 (15.14) |
-3.01% | Details | |
| 4/1/2026 | Entrada Therapeutics | TRDA | New Coverage | Overweight (N/A) |
12.62 (7.07) |
-43.98% | Details | |
| 3/11/2026 | Satellos Bioscience Inc. | MSLE | New Coverage | Overweight (N/A) |
9.54 (9.08) |
-4.82% | Details | |
| 3/6/2026 | Karyopharm Therapeutics | KPTI | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/5/2026 | Karyopharm Therapeutics | KPTI | New Coverage | Overweight (N/A) |
6.55 (1.85) |
-71.76% | Details |
